These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30583927)

  • 1. Is There a Role for an 18F-fluorodeoxyglucose-derived Biological Boost in Squamous Cell Anal Cancer?
    Sabbagh A; Jacobs C; Cooke R; Chu KY; Ng SM; Strauss VY; Virdee PS; Hawkins MA; Aznar MC; Muirhead R
    Clin Oncol (R Coll Radiol); 2019 Feb; 31(2):72-80. PubMed ID: 30583927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.
    Calais J; Dubray B; Nkhali L; Thureau S; Lemarignier C; Modzelewski R; Gardin I; Di Fiore F; Michel P; Vera P
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):858-67. PubMed ID: 25680400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET parameters predict for recurrence in anal cancer - results from a prospective, multicentre clinical trial.
    Jones MP; Hruby G; Metser U; Sridharan S; Capp A; Kumar M; Gallagher S; Rutherford N; Holder C; Oldmeadow C; Martin J
    Radiat Oncol; 2019 Aug; 14(1):140. PubMed ID: 31387597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
    Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
    Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma.
    Duimering A; Riauka T; Nijjar Y; Ghosh S; MacEwan R; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Nijjar T; Fairchild A; Mulder K; Doll C; Wong C; Joseph K
    Radiother Oncol; 2019 Jul; 136():21-28. PubMed ID: 31015125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
    Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer.
    Wilson JM; Mukherjee S; Chu KY; Brunner TB; Partridge M; Hawkins M
    Radiat Oncol; 2014 Jun; 9():146. PubMed ID: 24962658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3).
    Palie O; Michel P; Ménard JF; Rousseau C; Rio E; Bridji B; Benyoucef A; Meyer ME; Jalali K; Bardet S; M'vondo CM; Olivier P; Faure G; Itti E; Diana C; Houzard C; Mornex F; Di Fiore F; Vera P
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1345-55. PubMed ID: 23715903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
    Winton Ed; Heriot AG; Ng M; Hicks RJ; Hogg A; Milner A; Leong T; Fay M; MacKay J; Drummond E; Ngan SY
    Br J Cancer; 2009 Mar; 100(5):693-700. PubMed ID: 19259091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG PET using SUV
    Huang YC; Lu HI; Huang SC; Hsu CC; Chiu NT; Wang YM; Chiu YC; Li SH
    BMC Med Imaging; 2017 Jan; 17(1):1. PubMed ID: 28056868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of 18F-FDG PET-derived parameters for predicting complete response to chemoradiotherapy in squamous cell anal carcinoma.
    Filippi L; Fontana A; Spinelli GP; Rossi L; Bagni O
    Nucl Med Commun; 2020 Oct; 41(10):1089-1094. PubMed ID: 32732599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
    Yap ML; Sun A; Higgins J; Clarke K; Marshall A; Becker N; Le LW; Vines DC; Bezjak A; Bissonnette JP
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e199-e205. PubMed ID: 27637725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive Boost Target Definition in High-Risk Head and Neck Cancer Based on Multi-imaging Risk Biomarkers.
    Teng F; Aryal M; Lee J; Lee C; Shen X; Hawkins PG; Mierzwa M; Eisbruch A; Cao Y
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):969-977. PubMed ID: 29428251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.
    Day FL; Link E; Ngan S; Leong T; Moodie K; Lynch C; Michael M; Winton Ed; Hogg A; Hicks RJ; Heriot A
    Br J Cancer; 2011 Aug; 105(4):498-504. PubMed ID: 21792197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer.
    Shusharina N; Cho J; Sharp GC; Choi NC
    Int J Radiat Oncol Biol Phys; 2014 May; 89(1):137-44. PubMed ID: 24725696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-dimensional positron emission tomography: implications for dose painting of high-uptake regions.
    Aristophanous M; Yap JT; Killoran JH; Chen AB; Berbeco RI
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):900-8. PubMed ID: 20950956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II-III NSCLC.
    La Fontaine M; Vogel W; van Diessen J; van Elmpt W; Reymen B; Persson G; Westman G; De Ruysscher D; Belderbos J; Sonke JJ
    Radiother Oncol; 2018 May; 127(2):259-266. PubMed ID: 29709378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of
    Wilson JM; Mukherjee S; Brunner TB; Partridge M; Hawkins MA
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):370-377. PubMed ID: 28190636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.